在 COVID-19 大流行之前和第一年期间,美国大麻合法化和阿片类药物死亡率趋势。

Q3 Medicine Journal of opioid management Pub Date : 2024-03-01 DOI:10.5055/jom.0829
Archie Bleyer, Brian Barnes, Kenneth Finn
{"title":"在 COVID-19 大流行之前和第一年期间,美国大麻合法化和阿片类药物死亡率趋势。","authors":"Archie Bleyer, Brian Barnes, Kenneth Finn","doi":"10.5055/jom.0829","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To determine if marijuana legalization was associated with reduced opioid mortality.</p><p><strong>Study design: </strong>The United States (US) opioid mortality trend during the 2010-2019 decade was compared in states and District of Columbia (jurisdictions) that had implemented marijuana legalization with states that had not. Acceleration of opioid mortality during 2020, the first year of the coronavirus disease 2019 (COVID-19) pandemic, was also compared in recreational and medicinal-only legalizing jurisdictions.</p><p><strong>Methods: </strong>Joinpoint methodology was applied to the Centers for Disease Control and Prevention WONDER data. Trends in legalizing jurisdictions were cumulative aggregates.</p><p><strong>Results: </strong>The overall opioid and fentanyl death rates and the percentage of opioid deaths due to fentanyl increased more during 2010-2019 in jurisdictions that legalized marijuana than in those that did not (pairwise comparison p = 0.007, 0.05, and 0.006, respectively). By 2019, the all-opioid and fentanyl death rates were 44 and 50 percent greater in the legalizing than in the nonlegalizing jurisdictions, respectively. When the COVID-19 pandemic hit in 2020, jurisdictions that implemented recreational marijuana legalization before 2019 had significantly greater increases in both overall opioid and fentanyl death rates than jurisdictions with medicinal-only legalization. For all-opioids, the mean (95 percent confidence interval) 2019-to-2020 increases were 46.5 percent (36.6, 56.3 percent) and 29.1 percent (20.2, 37.9 percent), respectively (p = 0.02). For fentanyl, they were 115.6 percent (80.2, 151.6 percent) and 55.4 percent (31.6, 79.2 percent), respectively (p = 0.01).</p><p><strong>Conclusions: </strong>During the past decade, marijuana legalization in the US was associated at the jurisdiction level with a greater acceleration in opioid death rate. An even greater increase in opioid mortality occurred in recreational-legalizing jurisdictions with the onset of the COVID-19 pandemic. Marijuana legalization is correlated with worsening of the US opioid epidemic.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"20 2","pages":"119-132"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"United States marijuana legalization and opioid mortality trends before and during the first year of the COVID-19 pandemic.\",\"authors\":\"Archie Bleyer, Brian Barnes, Kenneth Finn\",\"doi\":\"10.5055/jom.0829\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To determine if marijuana legalization was associated with reduced opioid mortality.</p><p><strong>Study design: </strong>The United States (US) opioid mortality trend during the 2010-2019 decade was compared in states and District of Columbia (jurisdictions) that had implemented marijuana legalization with states that had not. Acceleration of opioid mortality during 2020, the first year of the coronavirus disease 2019 (COVID-19) pandemic, was also compared in recreational and medicinal-only legalizing jurisdictions.</p><p><strong>Methods: </strong>Joinpoint methodology was applied to the Centers for Disease Control and Prevention WONDER data. Trends in legalizing jurisdictions were cumulative aggregates.</p><p><strong>Results: </strong>The overall opioid and fentanyl death rates and the percentage of opioid deaths due to fentanyl increased more during 2010-2019 in jurisdictions that legalized marijuana than in those that did not (pairwise comparison p = 0.007, 0.05, and 0.006, respectively). By 2019, the all-opioid and fentanyl death rates were 44 and 50 percent greater in the legalizing than in the nonlegalizing jurisdictions, respectively. When the COVID-19 pandemic hit in 2020, jurisdictions that implemented recreational marijuana legalization before 2019 had significantly greater increases in both overall opioid and fentanyl death rates than jurisdictions with medicinal-only legalization. For all-opioids, the mean (95 percent confidence interval) 2019-to-2020 increases were 46.5 percent (36.6, 56.3 percent) and 29.1 percent (20.2, 37.9 percent), respectively (p = 0.02). For fentanyl, they were 115.6 percent (80.2, 151.6 percent) and 55.4 percent (31.6, 79.2 percent), respectively (p = 0.01).</p><p><strong>Conclusions: </strong>During the past decade, marijuana legalization in the US was associated at the jurisdiction level with a greater acceleration in opioid death rate. An even greater increase in opioid mortality occurred in recreational-legalizing jurisdictions with the onset of the COVID-19 pandemic. Marijuana legalization is correlated with worsening of the US opioid epidemic.</p>\",\"PeriodicalId\":16601,\"journal\":{\"name\":\"Journal of opioid management\",\"volume\":\"20 2\",\"pages\":\"119-132\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of opioid management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5055/jom.0829\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of opioid management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5055/jom.0829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

研究背景研究设计:研究设计:比较了已实施大麻合法化的州和哥伦比亚特区(辖区)与未实施大麻合法化的州在 2010-2019 十年间的阿片类药物死亡率趋势。此外,还比较了 2020 年(即冠状病毒病 2019 年(COVID-19)大流行的第一年)期间阿片类药物死亡率的加速情况:方法:对美国疾病控制和预防中心的 WONDER 数据采用了连接点方法。结果:阿片类药物和芬太尼类药物的总体下降率为 0.5%,而阿片类药物和芬太尼类药物的下降率为 0.5%:2010-2019年期间,在大麻合法化的辖区,阿片类药物和芬太尼的总死亡率以及因芬太尼导致的阿片类药物死亡所占百分比的增长幅度高于未合法化的辖区(成对比较的P = 0.007、0.05和0.006)。到 2019 年,大麻合法化辖区的全阿片类药物死亡率和芬太尼死亡率分别比未合法化辖区高出 44% 和 50%。当 COVID-19 在 2020 年大流行时,在 2019 年之前实施娱乐性大麻合法化的辖区的阿片类药物和芬太尼类药物总死亡率的增幅明显高于仅实施药用合法化的辖区。就所有阿片类药物而言,2019 年至 2020 年的平均增幅(95% 置信区间)分别为 46.5%(36.6%,56.3%)和 29.1%(20.2%,37.9%)(p = 0.02)。芬太尼的增幅分别为 115.6%(80.2%,151.6%)和 55.4%(31.6%,79.2%)(P = 0.01):结论:在过去十年中,美国大麻合法化与辖区内阿片类药物死亡率的加速增长有关。随着 COVID-19 大流行的爆发,娱乐合法化辖区的阿片类药物死亡率甚至出现了更大幅度的增长。大麻合法化与美国阿片类药物流行病的恶化有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
United States marijuana legalization and opioid mortality trends before and during the first year of the COVID-19 pandemic.

Background: To determine if marijuana legalization was associated with reduced opioid mortality.

Study design: The United States (US) opioid mortality trend during the 2010-2019 decade was compared in states and District of Columbia (jurisdictions) that had implemented marijuana legalization with states that had not. Acceleration of opioid mortality during 2020, the first year of the coronavirus disease 2019 (COVID-19) pandemic, was also compared in recreational and medicinal-only legalizing jurisdictions.

Methods: Joinpoint methodology was applied to the Centers for Disease Control and Prevention WONDER data. Trends in legalizing jurisdictions were cumulative aggregates.

Results: The overall opioid and fentanyl death rates and the percentage of opioid deaths due to fentanyl increased more during 2010-2019 in jurisdictions that legalized marijuana than in those that did not (pairwise comparison p = 0.007, 0.05, and 0.006, respectively). By 2019, the all-opioid and fentanyl death rates were 44 and 50 percent greater in the legalizing than in the nonlegalizing jurisdictions, respectively. When the COVID-19 pandemic hit in 2020, jurisdictions that implemented recreational marijuana legalization before 2019 had significantly greater increases in both overall opioid and fentanyl death rates than jurisdictions with medicinal-only legalization. For all-opioids, the mean (95 percent confidence interval) 2019-to-2020 increases were 46.5 percent (36.6, 56.3 percent) and 29.1 percent (20.2, 37.9 percent), respectively (p = 0.02). For fentanyl, they were 115.6 percent (80.2, 151.6 percent) and 55.4 percent (31.6, 79.2 percent), respectively (p = 0.01).

Conclusions: During the past decade, marijuana legalization in the US was associated at the jurisdiction level with a greater acceleration in opioid death rate. An even greater increase in opioid mortality occurred in recreational-legalizing jurisdictions with the onset of the COVID-19 pandemic. Marijuana legalization is correlated with worsening of the US opioid epidemic.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of opioid management
Journal of opioid management Medicine-Anesthesiology and Pain Medicine
CiteScore
1.00
自引率
0.00%
发文量
54
期刊介绍: The Journal of Opioid Management deals with all aspects of opioids. From basic science, pre-clinical, clinical, abuse, compliance and addiction medicine, the journal provides and unbiased forum for researchers and clinicians to explore and manage the complexities of opioid prescription.
期刊最新文献
A pilot study to examine the opioid prescribing practices of medical residents. Buprenorphine: An anesthesia-centric review. Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients. Insurance coverage and consistent pricing is needed for over-the-counter naloxone. Naloxone coprescribing best practice advisory for patients at high risk for opioid-related adverse events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1